Cue Biopharma, Inc.
CUE
$0.7007
$0.04526.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.08% | -9.65% | 14.86% | 17.62% | 8.09% |
| Total Depreciation and Amortization | -95.08% | 245.25% | -187.59% | 1,528.28% | -96.69% |
| Total Amortization of Deferred Charges | 0.00% | -10.00% | 11.11% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 411.29% | -118.15% | 266.76% | -61.96% | 2,155.37% |
| Change in Net Operating Assets | 302.44% | 29.17% | 48.67% | -804.38% | 57.65% |
| Cash from Operations | 9.48% | -19.94% | 24.65% | -2.11% | 10.71% |
| Capital Expenditure | -7,400.00% | -300.00% | 110.00% | 81.82% | -- |
| Sale of Property, Plant, and Equipment | -- | -98.97% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -14,900.00% | -101.02% | 1,080.00% | 81.82% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.10% | 0.10% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -99.38% | -- | -100.00% | -41.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.30% | -109.49% | 1,082.10% | -142.48% | -50.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.42% | -516.43% | 121.75% | -46.96% | -21.19% |